Simplicity Wealth LLC Has $2.22 Million Position in Abbott Laboratories $ABT

Simplicity Wealth LLC lessened its stake in shares of Abbott Laboratories (NYSE:ABT) by 48.6% in the third quarter, according to the company in its most recent filing with the SEC. The fund owned 16,552 shares of the healthcare product maker’s stock after selling 15,674 shares during the quarter. Simplicity Wealth LLC’s holdings in Abbott Laboratories were worth $2,217,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also bought and sold shares of the company. Carr Financial Group Corp boosted its holdings in shares of Abbott Laboratories by 2.0% during the third quarter. Carr Financial Group Corp now owns 3,880 shares of the healthcare product maker’s stock worth $520,000 after acquiring an additional 76 shares during the period. Tortoise Investment Management LLC lifted its holdings in Abbott Laboratories by 10.7% during the 2nd quarter. Tortoise Investment Management LLC now owns 795 shares of the healthcare product maker’s stock worth $108,000 after purchasing an additional 77 shares during the last quarter. Gemmer Asset Management LLC boosted its stake in Abbott Laboratories by 2.9% in the 3rd quarter. Gemmer Asset Management LLC now owns 2,750 shares of the healthcare product maker’s stock valued at $368,000 after purchasing an additional 78 shares during the period. Charles Schwab Trust Co increased its position in Abbott Laboratories by 0.6% during the 2nd quarter. Charles Schwab Trust Co now owns 14,018 shares of the healthcare product maker’s stock worth $1,907,000 after buying an additional 79 shares during the period. Finally, Bridgewater Advisors Inc. lifted its holdings in shares of Abbott Laboratories by 0.6% during the second quarter. Bridgewater Advisors Inc. now owns 12,555 shares of the healthcare product maker’s stock worth $1,607,000 after buying an additional 79 shares in the last quarter. Institutional investors and hedge funds own 75.18% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts recently commented on ABT shares. Benchmark began coverage on shares of Abbott Laboratories in a research note on Friday, October 10th. They issued a “buy” rating and a $145.00 price target on the stock. Wells Fargo & Company increased their target price on shares of Abbott Laboratories from $142.00 to $146.00 and gave the stock an “overweight” rating in a research report on Thursday, October 16th. Raymond James Financial lifted their price target on shares of Abbott Laboratories from $141.00 to $146.00 and gave the company an “outperform” rating in a research report on Thursday, October 16th. Mizuho increased their price target on Abbott Laboratories from $135.00 to $140.00 and gave the stock a “neutral” rating in a research report on Tuesday, October 14th. Finally, Barclays lifted their price objective on Abbott Laboratories from $162.00 to $169.00 and gave the company an “overweight” rating in a report on Monday, January 5th. Two analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and three have assigned a Hold rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $147.39.

Abbott Laboratories Stock Down 10.1%

Shares of ABT opened at $108.50 on Friday. The firm has a 50 day simple moving average of $125.23 and a two-hundred day simple moving average of $128.54. The company has a debt-to-equity ratio of 0.23, a current ratio of 1.70 and a quick ratio of 1.24. Abbott Laboratories has a one year low of $105.78 and a one year high of $141.23. The company has a market cap of $188.67 billion, a P/E ratio of 13.60, a P/E/G ratio of 2.00 and a beta of 0.72.

Abbott Laboratories (NYSE:ABT) last issued its earnings results on Thursday, January 22nd. The healthcare product maker reported $1.50 earnings per share for the quarter, meeting analysts’ consensus estimates of $1.50. Abbott Laboratories had a return on equity of 17.60% and a net margin of 31.88%.The firm had revenue of $11.46 billion for the quarter, compared to the consensus estimate of $11.80 billion. During the same quarter last year, the business posted $1.34 EPS. The company’s revenue was up 4.4% compared to the same quarter last year. Abbott Laboratories has set its Q1 2026 guidance at 1.120-1.180 EPS and its FY 2026 guidance at 5.550-5.800 EPS. Research analysts forecast that Abbott Laboratories will post 5.14 EPS for the current fiscal year.

Abbott Laboratories Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, February 13th. Stockholders of record on Thursday, January 15th will be issued a $0.63 dividend. This represents a $2.52 dividend on an annualized basis and a dividend yield of 2.3%. This is an increase from Abbott Laboratories’s previous quarterly dividend of $0.59. The ex-dividend date of this dividend is Thursday, January 15th. Abbott Laboratories’s dividend payout ratio (DPR) is currently 31.58%.

Key Abbott Laboratories News

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: Med?tech / devices strength helped offset weakness elsewhere — management said Devices/MedTech delivered solid growth in Q4, cushioning the hit from Nutrition and Diagnostics. Read More.
• Positive Sentiment: Adjusted EPS and margins improved — adjusted EPS grew ~12% and matched street expectations, with margin gains driven by product mix and cost improvements. This supports the company’s cash generation and capital-return capacity. Read More.
• Neutral Sentiment: Reported EPS met consensus ($1.50), limiting the severity of the selloff from an earnings-surprise perspective. Read More.
• Negative Sentiment: Revenue missed expectations — Q4 revenue was below consensus ($~11.5B vs. ~$11.8B est), driven by a contraction in Nutrition (~?9%) and weakness in Diagnostics (lower COVID testing and aid-related volatility). That top?line miss is the main catalyst for the decline. Read More.
• Negative Sentiment: Guidance came in slightly below street models — Q1 EPS guide (1.120–1.180) and FY 2026 adjusted EPS (5.550–5.800) skated under consensus, which amplified selling pressure given the revenue shortfall. Read More.
• Negative Sentiment: Unusual bearish options activity — traders bought a large volume of puts (reported ~80,600), signaling elevated short?term hedging or directional bearish bets that can accelerate downward moves in the stock.
• Negative Sentiment: Market reaction and media coverage — widespread headlines on the revenue miss and weaker outlook pushed the shares lower and into fresh downside territory, with analysts noting the pullback even as most maintain constructive long?term views. Read More.

Abbott Laboratories Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.